Phase 1 dose-escalation trial of AG-270 in multiple tumor types carrying an MTAP deletion

Trial Profile

Phase 1 dose-escalation trial of AG-270 in multiple tumor types carrying an MTAP deletion

Planning
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs AG-270 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Jan 2018 According to a company media release, company has got the FDA clearance of an IND application for AG-270, a MAT2A inhibitor, targeting MTAP-deleted tumors.
    • 28 Dec 2017 New trial record
    • 26 Dec 2017 According to a company media release, Agios expects to initiate the Phase 1 trial in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top